ArticleJournal of inflammation research2026
A Machine Learning-Based Nomogram for Predicting Overall Survival in BCLC Stage 0-B Hepatocellular Carcinoma Patients with Low HALP Score.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score in patients with Barcelona Clinic Liver Cancer (BCLC) stage 0-B hepatocellular carcinoma (HCC) and to develop a prognostic nomogram for the low-HALP subgroup. Patients and Methods: We retrospectively analyzed 1,281 patients with BCLC stage 0-B HCC treated at Beijing Ditan Hospital between 2015 and 2021. Using a HALP cutoff of 47, patients were divided into a low‑HALP group (n = 457) and a high‑HALP group (n = 824). The low‑HALP cohort was randomly divided into a derivation set (n = 305) and an internal validation set (validation set 1, n = 152). An additional temporal validation set (validation set 2) comprised 251 patients treated between 2022 and 2025. Candidate predictors of 5‑year overall survival (OS) were screened using random survival forest, LASSO regression, and multivariate Cox analysis. A nomogram was then built and assessed by time‑dependent ROC curves, calibration plots, and decision curve analysis (DCA). Survival differences between risk groups were compared using the Kaplan-Meier method. Results: A high HALP score was significantly associated with longer OS (p < 0.001). The final nomogram included gamma‑glutamyl transferase, creatinine, C‑reactive protein, and BCLC stage. The AUCs for 1‑, 3‑, and 5‑year OS were 0.80, 0.75, and 0.77 in the derivation set; 0.80, 0.83, and 0.77 in validation set 1; and 0.79, 0.73, and 0.76 in validation set 2. Compared with conventional staging systems, the nomogram showed better discrimination for 5‑year OS. Calibration and decision curve analyses confirmed good agreement and clinical usefulness. Using an optimal cutoff of 9.5, the nomogram stratified patients into high‑ and low‑risk groups with markedly different 5‑year mortality rates: 86.9% versus 46.4% in the derivation set, 90.0% versus 43.4% in validation set 1, and 86.1% versus 43.5% in validation set 2. Conclusion: A low HALP score defines a subgroup of BCLC stage 0‑B HCC patients with poorer survival. To our knowledge, this is the first nomogram developed specifically for low‑HALP patients. It provides a tool for individualized prognostic assessment, although external validation is still needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.